China's Gaming Giant NetEase Stock Slides After Dismal Quarter

Benzinga
Feb 11

NetEase Inc. (NASDAQ:NTES) stock slid after it reported dismal fiscal fourth-quarter results on Wednesday.

The company’s quarterly revenue increased 3.0% year-on-year to $3.94 billion (27.55 billion Chinese yuan), missing the analyst consensus estimate of $4.10 billion.

The Chinese gaming player’s adjusted EPADS of $1.57 missed the analyst consensus estimate of $1.85.

Segments And Margins

Games and related value-added services revenues rose 3.4% to $3.14 billion. The corresponding gross margin increased by 384 bps to 70.5%, attributable to higher net revenues from self-developed games, such as Fantasy Westward Journey Online and newly launched games Where Winds Meet and Marvel Rivals.

Youdao (NYSE:DAO) revenue rose by 16.8% to $223.75 million. However, the corresponding gross margin declined by 274 bps to 45.1%.

NetEase Cloud Music’s revenues were $281.46 million, up 4.7%, while its gross margin expanded by 273 bps to 34.7%.

Innovative businesses and other revenue declined 10.4% to $292.77. However, the gross margin increased by 176 bps to 39.6%.

As of December 31, 2025, NetEase held $23.4 billion in cash and equivalents. The company generated $2.12 billion in operating cash flow during the quarter.

Dividend

The board of directors approved a dividend of 23.2 cents per share ($1.16 per ADS) for the fourth quarter of 2025 to holders of ordinary shares and holders of ADSs. NetEase paid a dividend of 11.4 cents per share (57 cents per ADS) for the third quarter of 2025 in December 2025.

NetEase CEO William Ding emphasized that AI has become a core component of their development and operations, significantly enhancing production efficiency and creating new interactive experiences for players.

“AI has become a foundational competency for our development and operations,” Ding said.

NTES Price Action: NetEase shares were down 4.13% at $118.42 during premarket trading on Wednesday, according to Benzinga Pro data.

Photo by Sergei Elagin via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10